Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash-to-Debt No Debt
NAS:ATRI's Cash-to-Debt is ranked higher than
97% of the 189 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.62 vs. NAS:ATRI: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
NAS:ATRI' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.01  Med: N/A Max: No Debt
Current: No Debt
Equity-to-Asset 0.89
NAS:ATRI's Equity-to-Asset is ranked higher than
94% of the 184 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.58 vs. NAS:ATRI: 0.89 )
Ranked among companies with meaningful Equity-to-Asset only.
NAS:ATRI' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.25  Med: 0.75 Max: 0.89
Current: 0.89
0.25
0.89
Interest Coverage No Debt
NAS:ATRI's Interest Coverage is ranked higher than
95% of the 133 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 45.06 vs. NAS:ATRI: No Debt )
Ranked among companies with meaningful Interest Coverage only.
NAS:ATRI' s Interest Coverage Range Over the Past 10 Years
Min: 80.46  Med: No Debt Max: No Debt
Current: No Debt
Piotroski F-Score: 7
Altman Z-Score: 33.28
Beneish M-Score: -2.74
WACC vs ROIC
6.49%
25.02%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating Margin % 27.43
NAS:ATRI's Operating Margin % is ranked higher than
94% of the 187 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.86 vs. NAS:ATRI: 27.43 )
Ranked among companies with meaningful Operating Margin % only.
NAS:ATRI' s Operating Margin % Range Over the Past 10 Years
Min: 22.81  Med: 28.39 Max: 32.43
Current: 27.43
22.81
32.43
Net Margin % 20.98
NAS:ATRI's Net Margin % is ranked higher than
91% of the 187 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.79 vs. NAS:ATRI: 20.98 )
Ranked among companies with meaningful Net Margin % only.
NAS:ATRI' s Net Margin % Range Over the Past 10 Years
Min: 15.82  Med: 19.53 Max: 22.12
Current: 20.98
15.82
22.12
ROE % 19.31
NAS:ATRI's ROE % is ranked higher than
85% of the 182 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.30 vs. NAS:ATRI: 19.31 )
Ranked among companies with meaningful ROE % only.
NAS:ATRI' s ROE % Range Over the Past 10 Years
Min: 15.48  Med: 17.96 Max: 20.41
Current: 19.31
15.48
20.41
ROA % 17.10
NAS:ATRI's ROA % is ranked higher than
92% of the 191 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.23 vs. NAS:ATRI: 17.10 )
Ranked among companies with meaningful ROA % only.
NAS:ATRI' s ROA % Range Over the Past 10 Years
Min: 13.58  Med: 15.79 Max: 17.56
Current: 17.1
13.58
17.56
ROC (Joel Greenblatt) % 37.02
NAS:ATRI's ROC (Joel Greenblatt) % is ranked higher than
81% of the 190 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9.88 vs. NAS:ATRI: 37.02 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NAS:ATRI' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 26.8  Med: 39.39 Max: 48.1
Current: 37.02
26.8
48.1
3-Year Revenue Growth Rate 5.70
NAS:ATRI's 3-Year Revenue Growth Rate is ranked higher than
55% of the 148 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.10 vs. NAS:ATRI: 5.70 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
NAS:ATRI' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -54.8  Med: 6.7 Max: 56.1
Current: 5.7
-54.8
56.1
3-Year EBITDA Growth Rate 3.90
NAS:ATRI's 3-Year EBITDA Growth Rate is ranked lower than
53% of the 126 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.80 vs. NAS:ATRI: 3.90 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
NAS:ATRI' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -40.1  Med: 13.35 Max: 131.8
Current: 3.9
-40.1
131.8
3-Year EPS without NRI Growth Rate 4.10
NAS:ATRI's 3-Year EPS without NRI Growth Rate is ranked higher than
50% of the 122 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.10 vs. NAS:ATRI: 4.10 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
NAS:ATRI' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -51.8  Med: 17.65 Max: 59.9
Current: 4.1
-51.8
59.9
GuruFocus has detected 7 Warning Signs with Atrion Corp $NAS:ATRI.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NAS:ATRI's 30-Y Financials

Financials (Next Earnings Date: 2017-08-09 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q2 2016

ATRI Guru Trades in Q2 2016

Jim Simons 28,500 sh (+1.79%)
Chuck Royce 43,641 sh (unchged)
» More
Q3 2016

ATRI Guru Trades in Q3 2016

Jim Simons 31,400 sh (+10.18%)
Chuck Royce 43,278 sh (-0.83%)
» More
Q4 2016

ATRI Guru Trades in Q4 2016

Jim Simons 33,200 sh (+5.73%)
Chuck Royce 42,878 sh (-0.92%)
» More
Q1 2017

ATRI Guru Trades in Q1 2017

Jim Simons 40,201 sh (+21.09%)
Chuck Royce 41,448 sh (-3.34%)
» More
» Details

Insider Trades

Latest Guru Trades with ATRI

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Instruments & Equipment » Medical Instruments & Supplies    NAICS: 339112    SIC: 3841
Compare:NAS:NVCR, NAS:LMNX, NAS:OSUR, NAS:IRTC, NAS:ATRC, NYSE:GKOS, NAS:ANGO, NAS:LMAT, NAS:NXTM, NAS:MLAB, OTCPK:GMDTF, AMEX:CRHM, NAS:ATRS, NAS:STAA, NAS:PLSE, NAS:ELGX, NAS:MMSI, NAS:ENTL, NYSE:HYH, NAS:UTMD » details
Headquarter Location:USA
Atrion Corp and its subsidiaries develop and manufacture products, for medical applications. Its medical products range from fluid delivery devices to ophthalmic and cardiovascular products.

Atrion Corp is incorporated in Delaware. The Company and its subsidiaries develop and manufacture products, mainly for medical applications. Its medical products include fluid delivery devices to ophthalmic and cardiovascular products. Its fluid delivery products include proprietary valves that promote infection control and needle safety. It has developed a variety of luer syringe check valves and one-way valves designed to fill, hold and release controlled amounts of fluids or gasses on demand for use in various intubation, catheter and other applications. It also makes tubing clamps in a variety of materials and colors that are compatible with various grades of tubing and sterilization processes, and produce specialized intravenous sets for use in numerous applications including anesthesia and oncology. Its cardiovascular products include MPS2 Myocardial Protection System, or MPS2, a proprietary technology that delivers essential fluids and medications to the heart during open-heart surgery. The MPS2 integrates key functions relating to the delivery of solutions to the heart, such as varying the rate and ratio of oxygenated blood, crystalloid, potassium and other additives, and controlling temperature, pressure and other variables to allow simpler, more flexible management of this process, indicating improved patient outcomes. The MPS2 is the only device used in open-heart surgery that allows for the mixing of drugs into the bloodstream without diluting the blood. The MPS2 employs pump, temperature control and microprocessor technologies and includes a line of disposable products. It also develop and manufacture other cardiovascular products such as cardiac surgery vacuum relief valves; silicone vessel loops for retracting and occluding vessels in minimally invasive surgical procedures; inflation devices for balloon catheter dilation, stent deployment and fluid dispensing; as well as products used in heart bypass surgery to make a precision opening in the heart for attachment of the bypass vessels. The Company is a manufacturer of contact lens disinfection cases. It also manufacture a proprietary line of balloon catheters used in the treatment of nasolacrimal duct obstruction in children and adults. Nasolacrimal duct obstruction can cause a condition called epiphora, or chronic tearing. People affected by this condition experience excessive and uncontrollable tearing and often encounter infection as a result of nasolacrimal blockage. In addition, it manufactures and sells a line of products designed for safe needle and scalpel blade containment. It is also the manufacturer of inflation systems and valves used in marine and aviation safety products. It manufactures inflation systems and valves for products such as life vests, life rafts, inflatable boats, survival equipment, and other inflatable structures. It also produce one-way and two-way pressure relief valves for use on electronics cases, munitions cases, pressure vessels,

Top Ranked Articles about Atrion Corp

Atrion Reports First Quarter Results
Atrion Corporation Announces Election of New Director

ALLEN, Texas, March 13, 2017 (GLOBE NEWSWIRE) -- Atrion Corporation (NASDAQ:ATRI) today announced the election of Preston G. Athey as a director effective immediately. Mr. Athey recently retired after an extraordinary 38 year career with T. Rowe Price Associates. In 1991, he began managing the firm's Small-Cap Value Fund. Under his tutelage, fund assets grew from $45 million to $10 billion. Mr. Athey holds a BA degree from Yale University and an MBA degree from Stanford University. Mr. Athey brings a wealth of financial and operational experience, and will be another strong voice for our stockholders.
Atrion Corporation develops and manufactures products primarily for medical applications.  The Company’s website is www.atrioncorp.com.
Contact:
Jeffery Strickland
Vice President and Chief Financial Officer
(972) 390-9800


Read more...

Ratios

vs
industry
vs
history
PE Ratio 33.12
ATRI's PE Ratio is ranked lower than
51% of the 118 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 31.48 vs. ATRI: 33.12 )
Ranked among companies with meaningful PE Ratio only.
ATRI' s PE Ratio Range Over the Past 10 Years
Min: 8.12  Med: 17.17 Max: 34.15
Current: 33.12
8.12
34.15
PE Ratio without NRI 33.12
ATRI's PE Ratio without NRI is ranked lower than
51% of the 119 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 31.38 vs. ATRI: 33.12 )
Ranked among companies with meaningful PE Ratio without NRI only.
ATRI' s PE Ratio without NRI Range Over the Past 10 Years
Min: 8.12  Med: 17.21 Max: 34.15
Current: 33.12
8.12
34.15
Price-to-Owner-Earnings 33.26
ATRI's Price-to-Owner-Earnings is ranked lower than
51% of the 80 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 29.93 vs. ATRI: 33.26 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
ATRI' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 10.21  Med: 20.41 Max: 38.02
Current: 33.26
10.21
38.02
PB Ratio 5.96
ATRI's PB Ratio is ranked lower than
68% of the 181 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.56 vs. ATRI: 5.96 )
Ranked among companies with meaningful PB Ratio only.
ATRI' s PB Ratio Range Over the Past 10 Years
Min: 1.23  Med: 2.95 Max: 5.99
Current: 5.96
1.23
5.99
PS Ratio 6.95
ATRI's PS Ratio is ranked lower than
74% of the 180 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.01 vs. ATRI: 6.95 )
Ranked among companies with meaningful PS Ratio only.
ATRI' s PS Ratio Range Over the Past 10 Years
Min: 1.36  Med: 3.36 Max: 6.98
Current: 6.95
1.36
6.98
Price-to-Free-Cash-Flow 33.57
ATRI's Price-to-Free-Cash-Flow is ranked lower than
56% of the 73 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 29.88 vs. ATRI: 33.57 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
ATRI' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 7.41  Med: 20.85 Max: 427.38
Current: 33.57
7.41
427.38
Price-to-Operating-Cash-Flow 25.16
ATRI's Price-to-Operating-Cash-Flow is ranked lower than
58% of the 95 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 19.90 vs. ATRI: 25.16 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
ATRI' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 5.98  Med: 13.25 Max: 25.27
Current: 25.16
5.98
25.27
EV-to-EBIT 23.89
ATRI's EV-to-EBIT is ranked higher than
65% of the 194 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 24.30 vs. ATRI: 23.89 )
Ranked among companies with meaningful EV-to-EBIT only.
ATRI' s EV-to-EBIT Range Over the Past 10 Years
Min: 1.1  Med: 11.4 Max: 24
Current: 23.89
1.1
24
EV-to-EBITDA 19.59
ATRI's EV-to-EBITDA is ranked higher than
52% of the 203 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 17.15 vs. ATRI: 19.59 )
Ranked among companies with meaningful EV-to-EBITDA only.
ATRI' s EV-to-EBITDA Range Over the Past 10 Years
Min: 1  Med: 9.1 Max: 19.68
Current: 19.59
1
19.68
PEG Ratio 6.13
ATRI's PEG Ratio is ranked lower than
79% of the 58 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.65 vs. ATRI: 6.13 )
Ranked among companies with meaningful PEG Ratio only.
ATRI' s PEG Ratio Range Over the Past 10 Years
Min: 0.22  Med: 1.74 Max: 7.76
Current: 6.13
0.22
7.76
Shiller PE Ratio 42.71
ATRI's Shiller PE Ratio is ranked higher than
58% of the 45 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 43.41 vs. ATRI: 42.71 )
Ranked among companies with meaningful Shiller PE Ratio only.
ATRI' s Shiller PE Ratio Range Over the Past 10 Years
Min: 14.82  Med: 29.1 Max: 42.89
Current: 42.71
14.82
42.89
Current Ratio 9.84
ATRI's Current Ratio is ranked higher than
95% of the 187 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.54 vs. ATRI: 9.84 )
Ranked among companies with meaningful Current Ratio only.
ATRI' s Current Ratio Range Over the Past 10 Years
Min: 0.89  Med: 3.8 Max: 10.37
Current: 9.84
0.89
10.37
Quick Ratio 6.84
ATRI's Quick Ratio is ranked higher than
93% of the 187 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.67 vs. ATRI: 6.84 )
Ranked among companies with meaningful Quick Ratio only.
ATRI' s Quick Ratio Range Over the Past 10 Years
Min: 0.87  Med: 1.9 Max: 7.18
Current: 6.84
0.87
7.18
Days Inventory 143.06
ATRI's Days Inventory is ranked lower than
62% of the 175 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 124.79 vs. ATRI: 143.06 )
Ranked among companies with meaningful Days Inventory only.
ATRI' s Days Inventory Range Over the Past 10 Years
Min: 114.19  Med: 132.65 Max: 143.06
Current: 143.06
114.19
143.06
Days Sales Outstanding 51.78
ATRI's Days Sales Outstanding is ranked higher than
86% of the 153 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 61.76 vs. ATRI: 51.78 )
Ranked among companies with meaningful Days Sales Outstanding only.
ATRI' s Days Sales Outstanding Range Over the Past 10 Years
Min: 34.8  Med: 40.01 Max: 51.78
Current: 51.78
34.8
51.78
Days Payable 19.07
ATRI's Days Payable is ranked lower than
94% of the 145 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 53.53 vs. ATRI: 19.07 )
Ranked among companies with meaningful Days Payable only.
ATRI' s Days Payable Range Over the Past 10 Years
Min: 16.14  Med: 20.52 Max: 25.4
Current: 19.07
16.14
25.4

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 0.74
ATRI's Dividend Yield % is ranked lower than
69% of the 148 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.15 vs. ATRI: 0.74 )
Ranked among companies with meaningful Dividend Yield % only.
ATRI' s Dividend Yield % Range Over the Past 10 Years
Min: 0.67  Med: 0.87 Max: 1.74
Current: 0.74
0.67
1.74
Dividend Payout Ratio 0.25
ATRI's Dividend Payout Ratio is ranked higher than
64% of the 85 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.30 vs. ATRI: 0.25 )
Ranked among companies with meaningful Dividend Payout Ratio only.
ATRI' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.13  Med: 0.17 Max: 0.26
Current: 0.25
0.13
0.26
3-Year Dividend Growth Rate 17.60
ATRI's 3-Year Dividend Growth Rate is ranked higher than
69% of the 64 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9.60 vs. ATRI: 17.60 )
Ranked among companies with meaningful 3-Year Dividend Growth Rate only.
ATRI' s 3-Year Dividend Growth Rate Range Over the Past 10 Years
Min: 0  Med: 2.2 Max: 45.5
Current: 17.6
0
45.5
Forward Dividend Yield % 0.77
ATRI's Forward Dividend Yield % is ranked lower than
76% of the 143 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.35 vs. ATRI: 0.77 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 1.58
ATRI's 5-Year Yield-on-Cost % is ranked lower than
51% of the 166 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.87 vs. ATRI: 1.58 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
ATRI' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 1.43  Med: 1.86 Max: 3.72
Current: 1.58
1.43
3.72
3-Year Average Share Buyback Ratio 2.90
ATRI's 3-Year Average Share Buyback Ratio is ranked higher than
96% of the 120 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: -3.20 vs. ATRI: 2.90 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ATRI' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -3.6  Med: -0.2 Max: 17
Current: 2.9
-3.6
17

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 37.94
ATRI's Price-to-Net-Cash is ranked lower than
77% of the 48 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 17.17 vs. ATRI: 37.94 )
Ranked among companies with meaningful Price-to-Net-Cash only.
ATRI' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 2.11  Med: 37.68 Max: 340.01
Current: 37.94
2.11
340.01
Price-to-Net-Current-Asset-Value 12.63
ATRI's Price-to-Net-Current-Asset-Value is ranked lower than
63% of the 109 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 8.18 vs. ATRI: 12.63 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
ATRI' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 1.58  Med: 9.53 Max: 372
Current: 12.63
1.58
372
Price-to-Tangible-Book 6.43
ATRI's Price-to-Tangible-Book is ranked lower than
54% of the 154 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.77 vs. ATRI: 6.43 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
ATRI' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.54  Med: 2.36 Max: 6.46
Current: 6.43
0.54
6.46
Price-to-Intrinsic-Value-Projected-FCF 2.57
ATRI's Price-to-Intrinsic-Value-Projected-FCF is ranked lower than
57% of the 82 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.03 vs. ATRI: 2.57 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
ATRI' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.25  Med: 1.49 Max: 12.43
Current: 2.57
0.25
12.43
Price-to-Intrinsic-Value-DCF (Earnings Based) 2.17
ATRI's Price-to-Intrinsic-Value-DCF (Earnings Based) is ranked lower than
52% of the 23 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.04 vs. ATRI: 2.17 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-DCF (Earnings Based) only.
N/A
Price-to-Median-PS-Value 2.07
ATRI's Price-to-Median-PS-Value is ranked lower than
81% of the 148 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.14 vs. ATRI: 2.07 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
ATRI' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.05  Med: 0.38 Max: 2.08
Current: 2.07
0.05
2.08
Price-to-Peter-Lynch-Fair-Value 5.65
ATRI's Price-to-Peter-Lynch-Fair-Value is ranked lower than
83% of the 42 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.21 vs. ATRI: 5.65 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
ATRI' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 0.32  Med: 0.94 Max: 7.74
Current: 5.65
0.32
7.74
Price-to-Graham-Number 3.08
ATRI's Price-to-Graham-Number is ranked lower than
56% of the 87 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.67 vs. ATRI: 3.08 )
Ranked among companies with meaningful Price-to-Graham-Number only.
ATRI' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 0.54  Med: 1.24 Max: 3.09
Current: 3.08
0.54
3.09
Earnings Yield (Greenblatt) % 4.20
ATRI's Earnings Yield (Greenblatt) % is ranked higher than
74% of the 267 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.18 vs. ATRI: 4.20 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
ATRI' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 4.18  Med: 8.75 Max: 93.4
Current: 4.2
4.18
93.4
Forward Rate of Return (Yacktman) % 8.25
ATRI's Forward Rate of Return (Yacktman) % is ranked lower than
53% of the 90 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9.64 vs. ATRI: 8.25 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
ATRI' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -14.6  Med: 12.4 Max: 68.2
Current: 8.25
-14.6
68.2

More Statistics

Revenue (TTM) (Mil) $145.8
EPS (TTM) $ 16.47
Beta0.71
Short Percentage of Float1.85%
52-Week Range $385.00 - 547.95
Shares Outstanding (Mil)1.84
» More Articles for NAS:ATRI

Headlines

Articles On GuruFocus.com
Atrion Reports First Quarter Results May 10 2017 
Atrion Corporation Announces Election of New Director Mar 13 2017 
Atrion Corporation Increases Quarterly Cash Dividend by 20% Aug 04 2015 
Atrion Reports Second Quarter Results Aug 04 2015 
Atrion Corporation Declares Quarterly Cash Dividend Nov 14 2014 
3 Cheap Health Care Dividend Stocks with Huge Potential to Grow Dividends Oct 02 2013 
Billionaires Hold Three Undervalued, Predictable Stocks with Yield Sep 16 2013 
26 Stocks Raised Dividends Over the Past Week Aug 18 2013 
My 4 Favorite Dividend Contenders with Highest Dividend Growth Potential May 24 2013 
Atrion Corporation: Track Record of Delivery Dec 03 2012 

More From Other Websites
Atrion Corporation Declares Quarterly Cash Dividend May 23 2017
ETFs with exposure to Atrion Corp. : May 22, 2017 May 22 2017
Atrion Corp. :ATRI-US: Earnings Analysis: Q1, 2017 By the Numbers : May 19, 2017 May 19 2017
Atrion posts 1Q profit May 10 2017
Atrion Reports First Quarter Results May 10 2017
Atrion Corp. – Value Analysis (NASDAQ:ATRI) : April 12, 2017 Apr 12 2017
Atrion Corp. breached its 50 day moving average in a Bullish Manner : ATRI-US : April 11, 2017 Apr 11 2017
Atrion Corp. breached its 50 day moving average in a Bullish Manner : ATRI-US : March 21, 2017 Mar 21 2017
Atrion Corporation Announces Election of New Director Mar 13 2017
Atrion Corp. breached its 50 day moving average in a Bearish Manner : ATRI-US : March 7, 2017 Mar 07 2017
Atrion Corp. :ATRI-US: Earnings Analysis: Q4, 2016 By the Numbers : March 3, 2017 Mar 03 2017
Atrion Corp. breached its 50 day moving average in a Bullish Manner : ATRI-US : February 24, 2017 Feb 24 2017
Atrion Corp. breached its 50 day moving average in a Bullish Manner : ATRI-US : January 30, 2017 Jan 30 2017
Atrion Corp. : ATRI-US: Dividend Analysis : December 01st, 2016 (record date) : By the numbers :... Jan 25 2017
ETFs with exposure to Atrion Corp. : January 19, 2017 Jan 19 2017
Is MedEquities Realty Trust Inc (MRT) a Good Stock to Buy? Dec 12 2016
Is Walker & Dunlop Inc. (WD) Going to Burn These Hedge Funds? Dec 12 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)